Akari Therapeutics, Plc (AKTX)Healthcare | Biotechnology | Boston, United States | NasdaqCM
5.80 USD
+0.68
(13.281%)
⇧
(April 17, 2026, 4 p.m.
EDT)
After hours: 5.93 +0.13 (2.241%) ⇧ (April 17, 2026, 7:22 p.m. EDT) Short-term: ★★☆☆☆ | Long-term: ★☆☆☆☆ | Dividends: ☆☆☆☆☆ |
Hot Take | April 19, 2026, 6:37 p.m. EDT
Despite massive insider buying and high analyst targets post-reverse split, the immediate trend is heavily bearish with a -23% projected 45-day downside; the stock is down ~88% year-to-date and lacks any dividend coverage. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.174767 |
| AutoARIMA | 0.195525 |
| AutoETS | 0.409756 |
| MSTL | 0.423819 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 45% |
| H-stat | 8.04 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.634 |
| Excess Kurtosis | -0.69 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 2.662 |
| Market Cap | 6,638,610 |
| Trailing P/E | Infinity |
| Forward P/E | -0.41 |
| Beta | 0.54 |
| Website | https://www.akaritx.com |
| Attribute | Value |
|---|---|
| 52 Week Change | -0.88671875 |
| Address1 | 22 Boston Wharf Road |
| Address2 | Floor 7 |
| All Time High | 95,200.0 |
| All Time Low | 3.25 |
| Ask | 0.1314 |
| Ask Size | 1 |
| Average Analyst Rating | 1.5 - Strong Buy |
| Average Daily Volume10 Day | 46,940 |
| Average Daily Volume3 Month | 16,096 |
| Average Volume | 16,096 |
| Average Volume10Days | 46,940 |
| Beta | 0.536 |
| Bid | 4.47 |
| Bid Size | 1 |
| Book Value | 25.031 |
| City | Boston |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 5.8 |
| Current Ratio | 0.442 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 6.0 |
| Day Low | 5.0826 |
| Debt To Equity | 2.662 |
| Display Name | Akari Therapeutics |
| Earnings Timestamp End | 1,755,892,800 |
| Earnings Timestamp Start | 1,755,547,200 |
| Ebitda | -12,081,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -43,960.3 |
| Enterprise Value | 531,084,378,112 |
| Eps Current Year | -12.0 |
| Eps Forward | -14.0 |
| Eps Trailing Twelve Months | 0.0 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fax | 929 274 7553 |
| Fifty Day Average | 7.56256 |
| Fifty Day Average Change | -1.7625599 |
| Fifty Day Average Change Percent | -0.23306392 |
| Fifty Two Week Change Percent | -88.671875 |
| Fifty Two Week High | 63.2 |
| Fifty Two Week High Change | -57.4 |
| Fifty Two Week High Change Percent | -0.90822786 |
| Fifty Two Week Low | 3.25 |
| Fifty Two Week Low Change | 2.5500002 |
| Fifty Two Week Low Change Percent | 0.78461546 |
| Fifty Two Week Range | 3.25 - 63.2 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,389,018,600,000 |
| Float Shares | 35,246,900,707 |
| Forward Eps | -14.0 |
| Forward P E | -0.41428572 |
| Free Cashflow | -10,221,500 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 5 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.24558 |
| Held Percent Institutions | 0.10401 |
| Implied Shares Outstanding | 1,144,588 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,774,915,200 |
| Last Split Factor | 1:40 |
| Long Business Summary | Akari Therapeutics, Plc, an oncology company, develops next-generation antibody-drug conjugates (ADC) for cancer-killing toxins. Its lead payload is PH1 to disrupt the function of spliceosomes and to trigger an immune response that leads to additional cancer cell killing. The company's lead product candidate is AKTX-101, a preclinical stage trop2-targeting ADC that combines PH1 with the trop2 antibody to treat solid tumor cancer types, including lung, breast, colon, and prostate. Its payloads include PH5, which inhibits DNA mismatch repair (MMR) and DNA damage response (DDR) to generate neoepitopes, and PH6, which inhibits DNA transcription in cancer cells and co-opted immune cells. The company also develops AKTX-102, a novel bispecific ADC that utilizes PH1 as its payload to treat various solid tumor cancers. Akari Therapeutics, Plc is headquartered in Boston, Massachusetts. |
| Long Name | Akari Therapeutics, Plc |
| Market | us_market |
| Market Cap | 6,638,610 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_306632341 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | -17,298,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 6,632,885 |
| Number Of Analyst Opinions | 3 |
| Open | 5.15 |
| Operating Cashflow | -10,568,000 |
| Operating Margins | 0.0 |
| Payout Ratio | 0.0 |
| Phone | 929 274 7510 |
| Post Market Change | 0.12999964 |
| Post Market Change Percent | 2.241373 |
| Post Market Price | 5.93 |
| Post Market Time | 1,776,468,174 |
| Previous Close | 5.12 |
| Price Eps Current Year | -0.48333335 |
| Price Hint | 2 |
| Price To Book | 0.23171268 |
| Profit Margins | 0.0 |
| Quick Ratio | 0.421 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.5 |
| Region | US |
| Regular Market Change | 0.6800003 |
| Regular Market Change Percent | 13.281256 |
| Regular Market Day High | 6.0 |
| Regular Market Day Low | 5.0826 |
| Regular Market Day Range | 5.0826 - 6.0 |
| Regular Market Open | 5.15 |
| Regular Market Previous Close | 5.12 |
| Regular Market Price | 5.8 |
| Regular Market Time | 1,776,456,000 |
| Regular Market Volume | 19,942 |
| Return On Assets | -0.15356 |
| Return On Equity | -0.6843 |
| Sand P52 Week Change | 0.38150132 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 1,144,588 |
| Shares Percent Shares Out | 0.0050999997 |
| Shares Short | 5,810 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 5,234 |
| Short Name | Akari Therapeutics Plc |
| Short Percent Of Float | 0.0185 |
| Short Ratio | 0.5 |
| Source Interval | 15 |
| State | MA |
| Symbol | AKTX |
| Target High Price | 280.0 |
| Target Low Price | 27.0 |
| Target Mean Price | 115.66667 |
| Target Median Price | 40.0 |
| Total Cash | 5,203,000 |
| Total Cash Per Share | 0.0 |
| Total Debt | 754,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | 0.0 |
| Trailing P E | Infinity |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 22.76364 |
| Two Hundred Day Average Change | -16.963638 |
| Two Hundred Day Average Change Percent | -0.74520767 |
| Type Disp | Equity |
| Volume | 19,942 |
| Website | https://www.akaritx.com |
| Zip | 2,210 |